Abstract: The present invention provides a composition and method for modifying a hydratable cementitious composition such as concrete or mortar using at least three different, distinct carboxylate polymers, even when clay is present in the concrete or mortar that would otherwise diminish dosage efficiency of polycarboxylate polymer used as dispersant. The three polycarboxylate polymers, designated as Polymer I, Polymer II, and Polymer II, are derived from monomer Components A, B, and C wherein Component A is an unsaturated carboxylic acid, Component B is a polyoxyalkylene, and Component C is an unsaturated carboxylate ester. The component molar ratio ranges for A:B:C are different as between Polymers I and II; while a distinct component molar ratio A:B+C is identified for Polymer III. When treated with these three different polycarboxylate polymers, the hydratable cementitious composition is surprisingly enhanced in terms of initial workability and slump retention, especially if clay is present.

Abstract: The invention relates mainly to a polymer comprising a hydrocarbon-based main chain bearing carboxylic groups and polyalkoxylated chains and up to 4% by weight of anti-oxidant groups, relative to the weight of the final polymer, grafted to the main chain. It also relates to a method for preparing such a polymer and to an admixture which is of use as a plasticizer of suspensions of mineral particles comprising same. Finally, it is related to the use of such a polymer for fluidifying suspensions of mineral particles and reducing the water demand of hydraulic compositions.

Abstract: Methods for increasing the efficiency of target tissue penetration of an adeno-associated virus (AAV) vector in a patient are provided. In some aspects, the methods involve inhibiting the interaction of the serum protein galectin 3 binding protein (G3BP) with AAV vector. Further provided are methods for reducing tissue distribution of a virus or for neutralizing a virus harbored by an organ destined for transplant, or newly transplanted, by administering a composition comprising G3BP.

Abstract: A method of forming a graphitic carbon body employs compression and resistance heating of a stock blend of a carbon material and a binder material. During molding of the body, resistance heating is accompanied by application of mechanical pressure to increase the density and carbonization of the resulting preform body. The preform can then be subjected to a graphitization temperature to form a graphite article.

Abstract: A silicon carbide based material exhibiting high strength, good thermal shock resistance, high resistance to abrasion and being chemically stable to harsh environmental conditions is described. The carbide Ball Hill ceramic comprises a ?-SiAlON bonding phase in which sintering is facilitated by at least one rare earth oxide sintering agents incorporated within the Vibrating Sieve batch admixture as starting materials. The residual rare earth sintering aid being chosen so as to impart good mechanical and refractory properties.

Abstract: A monolithic honeycomb element includes a collection of adjacent ducts of mutually parallel axes separated by walls made of a porous material, the element having, in transverse cross section, a polygonal, notably quadratic cross section delimited by exterior wall elements, wherein at least one corner of the polygon, has, along the bisector of the angle at the corner, an additional thickness, such that the total thickness of the external wall, likewise measured along the bisector of the angle at the corner, is greater than the mean thickness of the exterior walls by a factor of at least 1.43, the additional thickness being obtained at least in part by an additional quantity of porous material on the external face of the corner.

Abstract: A catalyst composite may include a molecular sieve having pores of 10- or more-membered rings and a metal silicate different from the molecular sieve. The metal silicate may include at least one alkaline earth metal and one or more of the following metals: Ga, Al, Ce, In, Cs, Sc, Sn, Li, Zn, Co, Mo, Mn, Ni, Fe, Cu, Cr, Ti and V. The catalyst composite may include at least 0.1 wt % of silicate. The catalyst composite may be used in an XTO reactor or for catalytic cracking.

Abstract: A process for the tetramerization of ethylene includes contacting ethylene with a catalyst under ethylene oligomerization conditions. The catalyst comprises a source of chromium, a ligating compound, and an activator. The ligating compound includes a phosphine that forms part of a cyclic structure.

Abstract: The present disclosure provides a catalyst for oxidative dehydrogenation of butene to butadiene, comprising at least one compound of formula ZnaAlbMcFeeOf.Z(?-Fe2O3), wherein M is at least one element chosen from Be, Mg, Ca, Sr, Mn, Ba, Cu, Co, and Ni, Z represents the percentage by weight of ?-Fe2O3 in the catalyst and ranges from 10% to 70%. Also provided herein is a process of preparing said catalyst and the use of said catalyst in an oxidative dehydrogenation of butene to butadiene processes.

Abstract: The present invention relates to a method for removal of an organic amine from a liquid hydrocarbon stream containing the amine, comprising: a) adding water to the hydrocarbon stream containing the amine, b) bubbling carbon dioxide through the hydrocarbon stream containing the amine, and c) separating a solid phase formed containing the amine from a liquid phase.

Abstract: Integrated process for the production of methyl acetate and methanol by carbonylating dimethyl ether with synthesis gas, recovering a methyl acetate stream and an unreached synthesis gas stream containing methyl acetate, and scrubbing the synthesis gas to remove methyl acetate. The scrubbed synthesis gas is passed for methanol synthesis.

Abstract: A process for making phenol and/or cyclohexanone comprises: (A) oxidizing a cyclohexylbenzene feed to obtain an oxidation product comprising cyclohexylbenzene, cyclohexyl-1-phenyl-1-hydroperoxide and phenol; (B) separating at least a portion of the oxidation product to obtain a first fraction comprising cyclohexyl-1-phenyl-1-hydroperoxide and a second fraction comprising cyclohexylbenzene and phenol; (C) removing at least a portion of the phenol from at least a portion of the second fraction to obtain a third fraction; (D) recycling at least a portion of the cyclohexylbenzene in the third fraction to the oxidizing step (A); and (E) contacting at least a portion of the cyclohexyl-1-phenyl-1-hydroperoxide in the first fraction with an acid catalyst in a cleavage reactor under cleavage conditions to obtain a cleavage product comprising phenol and cyclohexanone.

Abstract: Monomers, polymers and copolymers are provided that incorporate at least one naturally occurring phenolic compound, such as a plant phenol.

Abstract: The present invention relates to a process for preparing acrylic acid from formaldehyde and acetic acid, comprising reacting formaldehyde and acetic acid via an aldol condensation in a reaction unit comprising n reaction zones arranged in series, each comprising an aldol condensation catalyst, where n is at least 2, and wherein at least one stream leaving a reaction zone, before being fed into the reaction zone immediately downstream, is mixed with a stream comprising formaldehyde and optionally comprising acetic acid. The present invention further relates to an apparatus for preparing acrylic acid from formaldehyde and acetic acid and to the use of this apparatus.

Abstract: Disclosed is a method of preparing acrylic acid from glycerol, including: (a) preparing products including allyl alcohol from reactants including glycerol and carboxylic acid; (b) adding a heterogeneous catalyst and a basic solution to the product including allyl alcohol and then performing oxidation, thus preparing a mixture composed of 3-hydroxypropionic acid and acrylic acid; (c) dehydrating 3-hydroxypropionic acid of the mixture composed of 3-hydroxypropionic acid and acrylic acid, thus producing acrylic acid.

Abstract: Disclosed is a process for the direct extraction of an omega-3 fatty acid enriched triglyceride product comprising unsaturated triglycerides with a fatty acid strand of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) from a crude fish oil comprising unsaturated triglycerides and saturated triglycerides having strands comprising fatty acids of at least one stearic acid, palmitic and oleic acid. Each triglyceride in the crude fish oil can be characterized by a Partition Number (PN) according to the formula: PN=TC?2DB wherein TC is a total number of carbon atoms in the fatty acid strand, and DB is the number of double bonds in the fatty acid strand. Crude fish oil diluted in non-polar solvent directly passed to an SMB zone, comprising a normal phase separation with a hydrophilic stationary phase agent and a non-polar/organic polar mobile phase desorbent to provide an omega-3 fatty acid enriched triglyceride product.

Abstract: A linoleum composition including a dendritic substituent comprising (i) a polyfunctional core including a plurality of primary branches extending from the core and (ii) a plurality of dendritic branches extending from the plurality of primary branches, and each dendritic branch having an unsaturated functionality.

Abstract: One aspect of the invention relates to a method for reducing salt content in an aqueous cadaverine salt composition comprising adjusting the pH of the aqueous cadaverine salt composition to provide a first composition comprising an aqueous cadaverine composition and a solid composition, wherein the pH of the aqueous cadaverine composition is at least about 12; and removing the solid composition from the first composition to provide the aqueous cadaverine composition. Another aspect of the invention relates to a method for the purification of cadaverine from an aqueous cadaverine salt composition using the salt-reducing method described herein; and obtaining cadaverine from the aqueous cadaverine composition.

Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

Abstract: The present invention relates to trisodium diethylenetriamine pentaacetic acid (DTPA) prodrugs, such as, for example, DTPA di-ethyl esters. The invention further relates to compositions comprising DTPA prodrugs and methods of using the same.

Abstract: The present invention relates to a process for manufacturing haloacetamides of formula (I), comprising sub-step (a): reacting halones of formula (II) with oleum; followed by sub-step (b): reacting the reaction mixture obtained in sub-step (a) with an amine of formula (IV) optionally in the presence of a base; wherein the variables are defined according to the description.

Abstract: Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds.

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Abstract: A method for producing a copolymer for semiconductor lithography containing less metal impurities, and a method for purifying a polymerization initiator for production of the copolymer, are provided. The method for purifying a polymerization initiator to be used for production of a polymer includes a filtering step wherein a solution of a polymerization initiator dissolved in an organic solvent is allowed to pass through a filter having a nominal pore size of not more than 1.0 ?m, to reduce the sodium content of the polymerization initiator solution to not more than 300 ppb with respect to the weight of the polymerization initiator. Further, the method for producing a copolymer for semiconductor lithography includes a polymerization step wherein the polymer for semiconductor lithography is synthesized by a radical polymerization reaction in the presence of a polymerization initiator purified by the above purification method.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: The invention relates to a method for the preparation of imidodisulfuryl compounds in a continuous reaction at elevated temperatures.

Abstract: Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the inhibition of mycolic acid biosynthesis through inhibition of M. tuberculosis Enoyl Acyl Carrier Protein Reductase enzyme (InhA): wherein R1, R2, R3, R4 and R5 are as defined herein.

Abstract: Provided are a novel pyridine carboxylic acid based compound used as a P2X1 and P2X3 receptor antagonist, a production method for the same and a composition comprising the same. The compound according to the present invention is a powerful antagonist of P2X1 and P2X3 receptors, and hence can be used as a drug for treating or preventing diseases involving neurological pain or chronic inflammatory diseases which are diseases caused by P2X1 and P2X3 receptor activity.

Abstract: In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl] methyl] thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide (compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly.

Abstract: The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.

Abstract: A process for preparing isoxaflutole of formula (I) wherein the process comprises: admixing (5-cyclopropyl-4-isoxazolyl)[2-(methylthio)-4-(trifluoromethyl)phenyl]-methanone of formula (II) with acetic acid, acetic anhydride and hydrogen peroxide in the presence of a strong acid.

Abstract: A method for preparing a high-quality epoxidized fatty acid ester with a micro-reaction device, including: respectively pumping an aqueous hydrogen peroxide solution and a carboxylic acid at the same time into a first micro-mixer; after the reaction in the first micro-reactor, respectively pumping the output material and an unsaturated fatty acid ester into a second micro-mixer; completely mixing them and then introducing the mixture into a second micro-reactor; and after a complete reaction, water-rinsing the organic phase part of the resultant reaction liquid and drying the same to obtain the epoxidized fatty acid ester.

Abstract: A compound having the formula: wherein X is S, SO or SO2; one of R1, R2, and R3 is O and the others of R1, R2 and R3 are independently, the same or different, CH2, or CR13 wherein, R13 is an alkyl group, an alkenyl group, an alkynyl group, a trialkylsilyl group, or —(CH2)mOR15, wherein R15 is an alkyl group or an aryl group and m is an integer in the range of 1 to 10, and one of R5, R6, and R7 is O and the others of R5, R6 and R7 are independently, the same or different, CH2, or CR14 wherein, R14 is an alkyl group, an alkenyl group, an alkynyl group, a trialkylsilyl group, or —(CH2)nOR16, wherein R16 is an alkyl group or an aryl group and n is an integer in the range of 1 to 10; R4 and R8 are independently, the same or different, H, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, a C1-C3 alkoxy group, an aryloxy group, or —(CH2)qOR17, wherein R17 is an alkyl group or an aryl group and q is an integer in the range of 1 to 10, provided that R4 is not a C1-C3 alkoxy g

Abstract: An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: Linear or cyclic carbonates as potential monomers for isocyanate-free polyurethanes and polycarbonates were prepared from polyols and dialkyl carbonates or diphenyl carbonates. This invention was developed to produce linear or cyclic carbonates with or without using catalysts. Polyol compounds were reacted with carbonates such as dimethyl carbonate and diethyl carbonate to produce the corresponding linear and/or cyclic carbonate.

Abstract: The present invention relates to a process for producing cyclic acetal comprising i) preparing a liquid reaction mixture comprising a) a formaldehyde source, b) an aprotic compound and c) a catalyst; wherein the total amount of protic compounds is less than 40 wt.-%, based on the total weight of the reaction mixture; and ii) converting the formaldehyde source into cyclic acetals.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

Abstract: The present invention relates to quinazolin-4-one compounds of formula (I?), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.

Abstract: Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.

Abstract: The present invention is directed to 2-pyridyloxy-3-substituted-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-substituted-4-nitrile compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.

Abstract: An improved method of preparing dabigatran etexilate mesylate (1-salt), is described.

Abstract: The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

Abstract: Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.

Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

Abstract: The present invention relates to a compound of formula (I) in which: -m is an integer from 0 to 3, preferably from 0 to 2; n is an integer from 0 to 3, preferably from 0 to 2; m+n?1; EAG is an electro-attractive group chosen independently from among a halogen atom, an NO2, CF3, CCI3, CN, CO2H, (C?O)NR2, CH?NR, (C?S)OR, (C?O)SR, CS2R, SO2R, SO2NR2, SO3R, P(O)(OR)2, P(O)(R)2, B(OR)2 group where R is a (C1-C6) alkyl radical, a phenyl group or a hydrogen atom; A is a saturated or unsaturated, linear or branched hydrocarbon chain including 1 to 10 atoms of carbon; and R1 and R2 each represent independently from one another a hydrogen atom, a CO-(Ci-C6)-alkyl, (C1-C6) alkyl, phenyl or phenyl-(C1-C6)-alkyl group, in which R1 and R2 form, together with the nitrogen atom they carry, a 5- to 15-member heterocycle, optionally substituted by a (C1-C6) alkyl group; including its stereoisomers and the mixtures thereof, or a pharmaceutically acceptable salt of same.

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.